News

Formulation and lyophilization process development for live virus vaccines

ProJect Pharmaceutics expands its service portfolio to meet customer’s increasing need for the development of GMO S2 and BSL-2 biological products including live viruses. ProJect Pharmaceutics is one of the leading European service providers offering tailored pharmaceutical formulations and lyophilisation processes for therapeutic proteins, peptides and other therapeutic compounds. New safety facilities in dedicated labs

Read More »

High Protein Concentration Formulations

Munich, October 29, 2015 – ProJect Pharmaceutics introduces a science-based approach to develop best-in-class formulations for convenient use in pre-filled syringes Transforming therapeutic proteins into high-concentrated, stable and easy to use medications for subcutaneous self-injection can add up to a major challenge along their clinical development. A formulation’s fundamental qualifications such as appropriate physico-chemical stability,

Read More »

Meet ProJect Pharmaceutics at Bio Korea 2015

Join Dr. Andreas Schütz for his presentation: “Formulation and lyophilization process development for biopharmaceutics” at Bio Korea 2015 from April 8–10, in Seoul, COEX international convention center. His talk is scheduled April 8th, 15:30 at Business/Technology Presentation Forum. Please contact our office at if you need further details on the conference or wish to

Read More »

Join Project Pharmaceutics at the upcoming World ADC

Project Pharmaceutics is glad to announce its participation as exhibitor at the upcoming World ADC Conference, taking place in Frankfurt, Germany, February 17-20, 2014. This conference will bring together international experts on ADCs from industries, universities and CROs.

Read More »

ProJect Pharmaceutics and TUM-Spin-off ImevaX announce agreement on development of pharmaceutical formulation for IMX101

Munich/Martinsried, November, 2013 ProJect Pharmaceutics announces that it has signed a development agreement with ImevaX, a spin-off project from the research group of Prof. Dr. Markus Gerhard from the Technische Universität München, Institute for Medicinal Microbiology, Immunology and Hygiene, aimed at developing a formulation for a recombinant vaccine against Helicobacter pylori. IMX101 is a multicomponent

Read More »

Introducing formulation and lyophilization process development for cytotoxic and other highly potent drugs

ProJect Pharmaceutics expands its service portfolio to meet customer’s increasing need for the development of cytotoxic and other highly potent drugs such as immunotoxins. ProJect Pharmaceutics is one of the leading European service providers offering tailored pharmaceutical formulations and lyophilisation processes for therapeutic proteins and peptides. New safety facilities in dedicated labs and a deep

Read More »